(BCHMF)

$74.45 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 300
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing...

Industry: Chemicals
Sector: Basic Materials
Phone: 41 58 595 2021
Fax: 41 58 595 2043
Address:
Hauptstrasse 144, Bubendorf, Switzerland
Fingerlickengood
Fingerlickengood Oct. 28 at 6:29 PM
$CDXS $BCHMF “three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale.”
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 28 at 5:03 PM
$CDXS Didnt realize $NVS has a manufacturing facility in Bubendorf, Switzerland...same place $BCHMF "is expected with regard to the previously communicated development plan for Building K. Bachem continues to expect that production of the first GMP batches can begin in 2025. While the commercial production in the inspected part will be ramped up in 2026, construction work in the remaining part of the building will continue." https://www.biospace.com/press-releases/bachem-announces-progress-in-building-k-start-up-and-expansion-of-its-site-in-vista-ca
2 · Reply
Fingerlickengood
Fingerlickengood Oct. 7 at 4:08 AM
$CDXS $BCHMF "ST Pharm announced said it has signed two new supply contracts worth a combined $18.25 million (24.9 billion won) with two U.S.-based global biotech companies for oligonucleotide active pharmaceutical ingredients (APIs). The deals include a $16.56 million agreement for a commercial cardiovascular treatment scheduled for first delivery in May 2026, and a $1.69 million contract for a new clinical-stage metabolic disease treatment, with delivery set for December 2025." https://www.koreabiomed.com/news/articleView.html?idxno=28087
1 · Reply
Fingerlickengood
Fingerlickengood Oct. 6 at 2:49 PM
$CDXS $BCHMF $ALNY "Efficient Large-scale siRNA Manufacturing" https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 8:34 PM
$CDXS $BCHMF 18 new positions in CA for Bachem, if this doesn't signify something BIG I dunno what does! The chemist position is telling speaking directly to an unnamed API! https://www.ziprecruiter.com/co/Bachem/Jobs
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 3:34 PM
$CDXS $BCHMF NOTE what it says: "Efficient Large-scale SiRNA Manufacturing" Why hasn't Codexis highlighted this webinar? Very suspect to say the least! https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
1 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 2:06 PM
$CDXS Have a feeling they are on the presipence of a major announcement with $BCHMF regarding US production of Inclisiran. Mark this post!
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:27 PM
$NVS You gotta wonder, where the specific enzyme was designed/synthesized that $CDXS and $BCHMF are now using in he ECO Lab to produce Inclisiran. This all seems too coincidental. https://www.codexis.com/investors/news-events/press-releases/detail/296/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 18 at 1:48 PM
$CDXS $BCHMF https://chemanager-online.com/en/topics/resilience-in-a-world-of-uncertainty
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 1:35 PM
$CDXS From 2nd quarter earnings: "In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis’ ligation processes to their in-house facilities." If $BCHMF, Nitto Avecia and ST Pharm incorporate the ECO Synthesis to some level across their manufacturing facilities equally, this will easily be a multibillion dollar company in the next few years! https://biz.chosun.com/en/en-science/2025/09/05/J42GIMB6MRC7XMX2532RSPWQAI/?outputType=amp
0 · Reply
Latest News on BCHMF
No data available.
Fingerlickengood
Fingerlickengood Oct. 28 at 6:29 PM
$CDXS $BCHMF “three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale.”
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 28 at 5:03 PM
$CDXS Didnt realize $NVS has a manufacturing facility in Bubendorf, Switzerland...same place $BCHMF "is expected with regard to the previously communicated development plan for Building K. Bachem continues to expect that production of the first GMP batches can begin in 2025. While the commercial production in the inspected part will be ramped up in 2026, construction work in the remaining part of the building will continue." https://www.biospace.com/press-releases/bachem-announces-progress-in-building-k-start-up-and-expansion-of-its-site-in-vista-ca
2 · Reply
Fingerlickengood
Fingerlickengood Oct. 7 at 4:08 AM
$CDXS $BCHMF "ST Pharm announced said it has signed two new supply contracts worth a combined $18.25 million (24.9 billion won) with two U.S.-based global biotech companies for oligonucleotide active pharmaceutical ingredients (APIs). The deals include a $16.56 million agreement for a commercial cardiovascular treatment scheduled for first delivery in May 2026, and a $1.69 million contract for a new clinical-stage metabolic disease treatment, with delivery set for December 2025." https://www.koreabiomed.com/news/articleView.html?idxno=28087
1 · Reply
Fingerlickengood
Fingerlickengood Oct. 6 at 2:49 PM
$CDXS $BCHMF $ALNY "Efficient Large-scale siRNA Manufacturing" https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 8:34 PM
$CDXS $BCHMF 18 new positions in CA for Bachem, if this doesn't signify something BIG I dunno what does! The chemist position is telling speaking directly to an unnamed API! https://www.ziprecruiter.com/co/Bachem/Jobs
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 3:34 PM
$CDXS $BCHMF NOTE what it says: "Efficient Large-scale SiRNA Manufacturing" Why hasn't Codexis highlighted this webinar? Very suspect to say the least! https://www.bachem.com/event/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
1 · Reply
Fingerlickengood
Fingerlickengood Oct. 3 at 2:06 PM
$CDXS Have a feeling they are on the presipence of a major announcement with $BCHMF regarding US production of Inclisiran. Mark this post!
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:27 PM
$NVS You gotta wonder, where the specific enzyme was designed/synthesized that $CDXS and $BCHMF are now using in he ECO Lab to produce Inclisiran. This all seems too coincidental. https://www.codexis.com/investors/news-events/press-releases/detail/296/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 18 at 1:48 PM
$CDXS $BCHMF https://chemanager-online.com/en/topics/resilience-in-a-world-of-uncertainty
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 1:35 PM
$CDXS From 2nd quarter earnings: "In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis’ ligation processes to their in-house facilities." If $BCHMF, Nitto Avecia and ST Pharm incorporate the ECO Synthesis to some level across their manufacturing facilities equally, this will easily be a multibillion dollar company in the next few years! https://biz.chosun.com/en/en-science/2025/09/05/J42GIMB6MRC7XMX2532RSPWQAI/?outputType=amp
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 29 at 8:02 PM
$CDXS $BCHMF $DHR If you want to cut to the chase on this, start listening at the 32 min mark, that delineates EVERYTHING about this company and making a sizeable investment here! GLTA and have a nice weekend.
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 26 at 3:17 PM
$CDXS Seems like management is intentionally allowing the sp to fall, in the meantime more large funds are buying it up hand over fist! https://www.codexis.com/investors/sec-filings/all-sec-filings/content/0000919574-25-004908/primary_doc.html $BCHMF $ALNY
1 · Reply
Fingerlickengood
Fingerlickengood Jul. 25 at 4:57 PM
$CDXS $BCHMF $NVO $ALNY This is starting to add up.... https://www.bachem.com/articles/news/bachem-novo-nordisk-redesign-spps-for-green-chemistry/
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 25 at 1:42 PM
$CDXS $BCHMF We are definitely in good company! https://www.koreabiomed.com/news/articleView.html?idxno=28359
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 24 at 1:06 PM
$CDXS $BCHMF "The Bachem Group (SIX: BANB) achieved sales of CHF 313.0 million in the first half of 2025 (+30.2% compared to the prior-year period: CHF 240.3 million). In local currencies (LC), sales increased by 34.1%." Great partner to have! https://www.newsfilecorp.com/release/259916/Bachem-Shows-Strong-Growth-in-the-First-Half-of-2025
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 24 at 1:04 PM
$CDXS $BCHMF "a scale-up of manufacturing needs is expected in the medium term, which again favors suppliers who can offer innovative solutions for more efficient production." Who does that sound like?! https://www.bachem.com/about-bachem/investors-and-media/reports-and-presentations/
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 23 at 2:29 PM
$CDXS $BCHMF This might be worth tuning into tomorrow... https://us06web.zoom.us/webinar/register/WN_OXMTQe3bRjKmtABLZ72Zyg#/registration
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 9 at 4:13 PM
$CDXS $BCHMF $LLY Im thinking the GMP inspection of the ECO Innovation Lab happened as they said last month by the FDA and are awaiting the final response from the FDA to move forward IOT begin commercial operations. Fingers crossed! https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmaceutical-inspections-and-compliance
1 · Reply
Fingerlickengood
Fingerlickengood Jul. 6 at 8:48 PM
$CDXS $BCHMF Was the FDA meeting in June regarding GLP regulations and approval of the ECO Synthesis Innovation Lab to scale production of siRNA material?
2 · Reply
Fingerlickengood
Fingerlickengood Jul. 3 at 3:23 PM
$CDXS $NVS $BCHMF Confirmed from a company update published and available on their (ST Pharm) website from 2021 when the COVID vaccine was the highlight of their work.....this is SIGNIFICANT imho! https://www.stpharm.co.kr/en/ir/ir-materials/analyst-report-developing-a-covid-19-mrna-vaccine
0 · Reply
Fingerlickengood
Fingerlickengood Jun. 24 at 9:58 PM
$CDXS $BCHMF
2 · Reply
Fingerlickengood
Fingerlickengood Jun. 6 at 7:55 PM
$CDXS $BCHMF $NVS $ALNY https://www.pharmacytimes.com/view/nla-2025-inclisiran-with-standard-care-provides-rapid-sustained-lowering-of-ldl-c-in-patients-with-recent-acute-coronary-syndrome
0 · Reply